Breast cancer screening in women at average risk and high risk

Obstetrics and Gynecology

Volumn 116, Issue 6, 2010, Pages 1410-1421

  Griffin, Jennifer L ^a   Pearlman, Mark D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST EXAMINATION; BREAST HYPERPLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL EXAMINATION; DIGITAL MAMMOGRAPHY; ECHOGRAPHY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; GYNECOLOGY; HEALTH CARE ORGANIZATION; HIGH RISK POPULATION; HUMAN; IMAGING SYSTEM; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTETRICS; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; AGED; BIOPSY; BREAST; BREAST NEOPLASMS; BREAST SELF-EXAMINATION; EARLY DETECTION OF CANCER; EVIDENCE-BASED PRACTICE; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; PALPATION; PRACTICE GUIDELINES AS TOPIC; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RISK FACTORS; ULTRASONOGRAPHY, MAMMARY;

EID: 78650142871     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181fe714e     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010.
3. Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
4. Humphrey L, Helfand M, Chan BKS, Woolf S. Breast cancer screening: a summary of the evidence for the United States Preventive Services Task Force. Ann Intern Med 2002;137(5 Part 1):347-60.
5. Pisani P, Parkin DM, Ngelangel C, Esteban D, Gibson L, Munson M, et al. Outcome of screening by clinical examination of the breast in a trial in the Philippines. Int J Cancer 2006;118:149-54.
6. Boulos S, Gadallah M, Neguib S, Essam E, Youssef A, Costa A, et al. Breast screening in the emerging world: high prevalence of breast cancer in Cairo. The Breast 2005;14:340-6.
7. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-Year Results of a Randomized Trial in Women Aged 50-59 Years. J Natl Cancer Inst 2000;92: 1490-9.
8. US Preventive Services Task Force. Screening for breast cancer: United States Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26, W-236.
9. Nelson H, Tyne K, Naik A, Bougatsos C, Chan B, Humphrey L. Screening for breast cancer: an update for the United States Preventive Services Task Force. Ann Intern Med 2009;151: 727-37, W237.
10. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009;151:738-47.
11. National Cancer Institute. Breast Cancer Surveillance Consortium: Evaluating Screening Performance in Practice. NIH Publication No. 04-5490. Bethesda (MD): National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services; April 2004.
12. Humphrey L, Helfand M, Chan BKS, Woolf S. Breast cancer screening: a summary of the evidence for the United States Preventive Services Task Force. Ann Intern Med 2002;137(5 Part 1):347-60. (Pubitemid 34977137)
13. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
14. Pisano E, Gatsonis C, Hendrick E, Yaffe M, Baum J, Acharyya S, et al. Diagnostic performance of digital versus film mam-mography for breast-cancer screening. N Engl J Med, The 2005;353:1773-83.
15. Birdwell RL. The preponderance of evidence supports computer-aided detection for screening mammography. Radiology 2009;253:9-16.
16. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338: 1089-96.
17. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false positive mammography results and detection of ductal carcinoma in situ: cross sectional survey. BMJ 2000;320:1635-40.
18. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 2007; 146:502-10.
19. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bö hm-Vélez M, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA 2008;299:2151-63.
20. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA 2005;293:1245-56.
21. Nothacker MDV, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S, Albert US Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer 2009;9:335.
22. Breast cancer screening and diagnosis. National Comprehensive Cancer Network practical guidelines in oncology 2010. Ft. Washington (PA): National Comprehensive Cancer Network; 2009.
23. Breast cancer facts and figures 2009-2010. Atlanta (GA): American Cancer Society; 2009.
24. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008;148:671-9.
25. Kriege M, Brekelmans CTM, Boetes C, Besnard P, Zonderland H, Obdeijn I, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
26. Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). The Lancet 2005;365:1769-78.
27. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mam-mography, and clinical breast examination. JAMA 2004;292: 1317-25. (Pubitemid 39223222)
28. Bobo JK, Lee NC, Thames SF. Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000;92:971-6.
29. Chiarelli AM, Majpruz V, Brown P, Theriault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst 2009;101: 1236-43.
30. Barton MB, Harris R, Fletcher SW. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA 1999;282:1270-80.
31. US Preventive Services Task Force. Screening for Breast Cancer: United States Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716-26, W-236.
32. Kosters J, Gotzsche P. Regular self-examination or clinical examination for early detection of breast cancer. The Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003373. DOI: 10.1002/14651858.CD003373.
33. Breast cancer screening. ACOG Practice Bulletin No. 42. American College of Obstetricians and Gynecologists. Obstet Gynecol 2003;101:821-31.
34. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst 2001;93:334-5.
35. Saslow D, Boetes C, Burke W, Harms S, Leach M, Lehman C. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA Cancer J Clin 2007;57:75-89.
36. BRCAPRO. BRCAPRO and information regarding licensing for this software. Available at: http://astor.som.jhmi.edu/Bayes Mendel/brcapro.html. Retrieved September 17, 2010.
37. Breast cancer risk reduction. National Comprehensive Cancer Network (NCCN) practical guidelines in oncology 2010. Ft. Washington (PA): National Comprehensive Cancer Network; 2009.
38. BOADICEA. Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA). Available at: http://www.srl.cam.ac.uk/genepi/ boadicea/boadicea home.html. Retrieved September 17, 2010.
39. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994;73:643-51.
40. Bhatia SR, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.
41. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeu-wen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-37.
42. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-88.
43. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:957-66.